Efficacy of Gemcitabine-based Chemotherapy in Clear Cell Sarcoma of Soft Tissue.

Abstract

BACKGROUND/AIM:

Clear cell sarcoma (CCS) is an aggressive sarcoma subtype, resistant to conventional anthracycline-based chemotherapy and radiation. The diagnosis is often challenging due to similarities with malignant melanoma.

PATIENTS AND METHODS:

We aimed to analyse the activity of gemcitabine-based chemotherapy in a cohort of patients with CCS treated at the Royal Marsden Hospital.

RESULTS:

Five patients with metastatic CCS received gemcitabine as first- or second-line systemic therapy. The median time-to-progression was 10 weeks. The median number of cycles of gemcitabine-based therapy was 3 (range=2-7 cycles). Median overall survival in our cohort was 66 months from the initial diagnosis but in the metastatic setting, the overall survival was reduced to 28 months.

CONCLUSION:

Gemcitabine-based therapy has modest activity in CCS. There remains a significant unmet medical need for novel, effective therapies for this disease.

• Authors: Elena Cojocaru, Khin Thway, Cyril Fisher, Christina Messiou, Shane Zaidi, Aisha B Miah, Charlotte Benson, Spyridon Gennatas, Paul Huang, Robin L Jones
• Journal: Anticancer research (Anticancer Res) Vol. 40 Issue 12 Pg. 7003-7007 (Dec 2020) ISSN: 1791-7530 [Electronic] Greece
• PMID: 33288595 (Publication Type: Case Reports, Journal Article)
• Copyright: Copyright © 2020 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Chemical References

• Antimetabolites, Antineoplastic
• Deoxycytidine
• Gemcitabine

Topics

• Adult
• Antimetabolites, Antineoplastic (pharmacology, therapeutic use)
• Deoxycytidine (analogs & derivatives, pharmacology, therapeutic use)
• Female
• Humans
• Male
• Middle Aged
• Sarcoma, Clear Cell (drug therapy)
• Soft Tissue Neoplasms (drug therapy)
• Gemcitabine